Author: cadams
-
Andarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29 in Andover, NH.
-
Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge , MA June 19-20.
-
Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018 in Gaithersburg, MD.
-
Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018.
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The data will be presented at…
-
A Billion Dollar Drug Using a Virtual Business Model
Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient
-
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.
-
Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market
Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights to the China market for Tozaride, a targeted peptide therapy. Wuxi Fortune and Andarix…
-
Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, IL June 2-6 2017.
-
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high SSTR expression levels…